Catestatin and Hypertension in Pregnancy

Relationship Between Catestatin and Pregnant Hypertensive Disorders

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03200743

Enrollment

400

Registered

2017-06-27

Start date

2017-05-14

Completion date

2017-12-31

Last updated

2017-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eclampsia, Hypertension in Pregnancy, Hypertension, Pregnancy-Induced, Pre-Eclampsia

Keywords

Hypertension, Pregnancy, Catestatin

Brief summary

Catestatin is a kind of protein involved with cardiovascular disease. Accumulated evidence shows that Catestatin may be a predictor of primary hypertension, but whether it plays the same role in pregnant hypertensive disorders needs to be determined. By measuring the plasma level of Catestatin, main biochemical marks and UCG in healthy pregnancy and pregnancy with hypertension, the research may contribute to this problem.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Healthy volunteers

Yes

Inclusion criteria

* Healthy pregnancy women * Pregnancy women with hypertension 1. Despite the pregnant gestational age , systolic blood pressure ≥140 mm Hg OR a diastolic blood pressure of ≥90 mm Hg measured three times more than 24 hours apart 2. Pregnant gestational age \> 20 weeks, systolic blood pressure ≥140 mm Hg OR a diastolic blood pressure of ≥90 mm Hg measured twice more than 4 hours apart

Exclusion criteria

* Lack of blood sample at the specified enrollment period * Women who refuse the study * Other illness which needs medications interfering with blood pressure (eg: Asthma requiring systemic steroids) * Known coronary artery disease or heart failure * Serious medical illness (eg: renal insufficiency, congestive heart disease, chronic respiratory insufficiency, uncontrolled infection). * multiple endocrine neoplasia or Cushing's syndrome or mixed tumours or pheochromocytoma or medullary thyroid carcinoma. * previous history of malignant tumour, with the exception of carcinoma in situ of the uterine cervix or non-melanoma skin cancer * renal insufficiency

Design outcomes

Primary

Measure	Time frame	Description
plasma level of Catestatin	once at the specified enrollment period	plasma level of Catestatin with the unit mmol/l

Secondary

Measure	Time frame	Description
blood pressure	the specified enrollment period,42 days and 2 months after the pregnancy	systolic and diastolic blood pressure with the unit mmHg

Countries

China

Contacts

Primary ContactYuchen Pan, MD

panyuchen@bjmu.edu.cn+8618810533382

Backup ContactDan Zhu, MD

andrea_zhu@163.com

Outcome results